Adjuvant Immunotherapy After Kidney Cancer Surgery — Who Actually Needs It

Most patients do not. After a kidney cancer is fully removed, and the pathology report shows a small, low-grade tumour confined to the kidney, the standard plan is surveillance — imaging and blood tests on a schedule, with no drug treatment. Adjuvant immunotherapy is discussed only for a selected high-risk group.

“Adjuvant” means after surgery, with nothing visible left. The operation has already removed the disease that could be seen. Adjuvant treatment is aimed at cells too few to show on any scan. That is what makes this decision different from treating advanced disease: there is no lump to measure, so there is no way to watch the treatment working.

The risk group is read off the surgical pathology report, not off how you feel or how big the scar is. Tumour size and stage, nuclear grade, sarcomatoid features, spread into the renal vein or beyond the kidney capsule, and whether a single secondary deposit was removed at the same operation all feed into it. Guideline recommendations here apply mainly to clear-cell renal cell carcinoma, the commonest subtype.

Several things rule it out. Non-clear-cell subtypes have far less evidence behind them and are usually discussed case by case. Active autoimmune disease, an organ transplant, or ongoing high-dose steroids can make checkpoint inhibitor treatment unsuitable or higher-risk, because it works by loosening restraints on the immune system rather than targeting the tumour directly.

Nothing on this page decides eligibility. That rests on the surgical pathology report, the stage, kidney function and overall fitness, read together by a medical oncologist.

The aim is to lower the chance of the cancer coming back. It is not treating anything visible, because surgery has already removed that. Trials of adjuvant immunotherapy in kidney cancer have not all pointed the same way, so the size of the benefit for any one person cannot be predicted.

That is a real disagreement in the evidence, not a hedge. NCCN lists adjuvant checkpoint immunotherapy as an option for a selected high-risk group after surgery for clear-cell kidney cancer. Other guideline bodies have been more cautious about recommending it as routine care, because separate trials in the same setting reported different results. Any page that gives you a single confident number for this is going beyond what the evidence supports.

This is also the point where the trade-off has to be said plainly. You feel well. The surgery is done. You are being asked to accept months of treatment that carries a real chance of immune-related side effects — some of which, such as thyroid or adrenal hormone changes, can need lifelong replacement — and a real cost, in exchange for a reduction in risk that cannot be measured in you personally.

Surveillance is a legitimate answer, not a refusal of care. It means scheduled CT imaging and clinical review at set intervals, so that a recurrence, if it comes, is found early and treated then. Kidney cancer that returns can still be treated, and the treatment options for advanced disease have changed considerably in the last few years. A decision explainer should include the option of not treating, and this one does.

One more thing worth raising, especially if the surgery was a few years ago. Adjuvant immunotherapy is a recent addition in kidney cancer. Plenty of patients were operated on before it became an option and were never offered the conversation at all. If nobody has raised it, that is worth asking about rather than assuming it did not apply.

Risk is estimated from features recorded at the time of surgery. No single line on the report decides it. The features below are read together, and the combination places the case either into routine surveillance or into the group where adjuvant treatment is worth discussing.

At CION this is a tumour-board decision — medical, surgical and radiation oncologists reading the report together — and the reasoning should be explained to you before anything is scheduled.

For a fixed, planned period — commonly about a year — and then it stops. Infusions are given as day care at set intervals, and the number of cycles is agreed before the first one. This is different from immunotherapy for advanced disease, where scan results decide whether treatment carries on.

The fixed end is one of the few genuinely reassuring things about this decision. It means the whole commitment is knowable in advance: how many cycles, how many hospital days, how many blood tests, and what the total will cost. Ask for that written out before cycle one rather than discovering it a few months in.

Two things can end the course early. The first is an immune-related side effect that needs treatment paused or stopped — the oncology team decides that, usually with steroids alongside. The second is a scan during the course showing the cancer has returned, which changes the plan from adjuvant treatment to treating visible disease, a different conversation entirely.

Surveillance imaging continues after the course finishes, whichever way the decision went. At CION, immunotherapy itself is given as day care at our centres, while the CT and PET-CT used for surveillance and response assessment are coordinated at partner imaging centres.

Because the course has a defined end, the total is knowable before you start. Ask for a written estimate for the whole planned course, not the price of a single cycle. A per-cycle figure sounds manageable and then multiplies into something the household was never shown.

• What a complete estimate should list — the number of cycles, the day-care charge, the blood tests before each cycle, the imaging done at set points, and what managing a side effect would add if one occurs. A steroid course, extra visits, and occasionally an admission are part of the real cost of this treatment.
• Cover, checked before cycle one — Aarogyasri and other scheme ceilings, CGHS, ECHS or ESI entitlement, and cashless insurance pre-authorisation are confirmed case by case at the centre. Scheme ceilings change, so what applied to someone else last year is not a safe guide.
• Ask about biosimilar options — biosimilar versions in the checkpoint inhibitor class have begun entering the Indian market, and that has started to move pricing in this class. Whether one applies to a particular plan is a question for the treating oncologist and the pharmacy, not something to assume either way.
• Say it out loud if the cost is the blocker — for adjuvant treatment the money is being spent on someone with no visible disease, so the cost question and the benefit question are really one question. Some blockers have answers: scheme cover, a different schedule, a biosimilar, or a clinical trial. None of them can be explored if the family simply stops coming.
• Choosing surveillance on cost grounds is a real decision — not a failure, and not something to be embarrassed about in front of the oncologist. It should be recorded as a decision, with the imaging schedule set, rather than left as a gap in follow-up.

By protocol, before every cycle. Creatinine, eGFR and urine protein are checked ahead of each infusion, alongside thyroid, liver function and blood counts. The schedule is fixed rather than symptom-driven, because the point is to detect a change before it is something you can feel.

• Baseline, before the first cycle — creatinine, eGFR, urine protein, thyroid, liver and blood counts are recorded as the reference every later result is compared against. Without a post-surgery baseline, a single later number means very little.
• Before every cycle after that — the same panel is repeated. A rising creatinine triggers review by the treating team; it is not automatically a reason to stop the course.
• Closer review after a kidney has been removed — with reduced kidney reserve, dehydration, contrast dye and some over-the-counter painkillers carry more weight than usual. Fluid intake and which painkillers are safe are agreed with the team, not assumed. If kidney function was already reduced before surgery, Immunotherapy on Dialysis or With Reduced Kidney Function covers how that changes the plan.
• Immune-related nephritis is a recognised, uncommon side effect — inflammation of the kidney can occur on checkpoint inhibitor treatment. Routine bloods usually pick it up before symptoms appear, and the oncology team manages it, commonly with steroids.
• What to report between cycles — a clear drop in how much urine you are passing, new swelling in the ankles or legs, or feeling unusually drowsy and unwell. Contact the treating team the same day rather than waiting for the next appointment. Urinary Symptoms During Immunotherapy: What Matters separates the changes that need a call from the ones that do not.

• Changes in passing urine are the thing patients notice first after a nephrectomy, and not all of them need a call — Urinary Symptoms During Immunotherapy: What Matters sorts the routine from the reportable.
• If kidney function was already reduced before the operation, or dialysis is part of the picture, Immunotherapy on Dialysis or With Reduced Kidney Function explains how that is handled.
• Organ function gates eligibility for immunotherapy in the same way elsewhere in the body — Child-Pugh Score and Immunotherapy Eligibility shows how a liver-function score is used to make the same kind of call.
• For how immunotherapy is delivered, monitored and paid for across our centres, see Immunotherapy at CION Cancer Clinics.

Still unsure whether adjuvant treatment applies after this surgery? Book a free consultation and a medical oncologist will read the pathology report with you.